Partner with us

Iconovo develops inhaler platforms at its own risk, with patent protection sought for all unique designs. Additionally, we advance suitable formulations and drug candidates up to pre-clinical PoC (Proof of Concept) or pilot PK (Pharmacokinetic) studies, before seeking partnerships for late-stage development and commercialization.

Revenue is primarily generated through upfront and milestone payments from partners during development, followed by royalties once the product reaches the market.

For interchangeable generic products, Iconovo generally retains rights for direct sales in the Nordics, as well as the mandate to manufacture and supply the inhalers. This arrangement offers a practical and economic solution for partners while providing a source of continuous income for Iconovo.